Biomedical Innovation Cities Development Forum --Promote Industry Development and Facilitate City Innovation

2020-11-02 13:57

In the afternoon of September 27, 2020, Biomedical Innovation Cities Development Forum (herein after referred to as “the Forum”) & Study Release Conference of “China Biomedical Innovation Cities with Most Investment Value (herein after referred to as “Study on Biomedical Innovation Cities”)” was successfully held in 2020 China BioMed Innovation and Investment Conference (2020 CBIIC)

Study on Biomedical Innovation Cities was initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA) and China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC) and conducted by IQVIA. IQVIA spent more than 5 months on this study, and made in-depth analysis on evaluation indicators of authoritative domestic and foreign city evaluation system, proposed representative and independent evaluation dimensions, constructed an evaluation index system and conducted a comprehensive evaluation on 72 selected cities.

Chen Deming, Former Minister of Commerce of the People’s Republic of China and Chairman of China Association of Enterprises with Foreign Investment (CAEFI), Bi Jingquan, Former Secretary of Party Group and Deputy Director General of CFDA, Ren Jinsheng, Chairman of PhIRDA, Song Ruilin, Executive President of PhIRDA, Cao Hongying, Executive Vice Chairman of CAEFI and Kang Wei, Managing Director of RDPAC etc. participated in the Forum. Representatives from government, pharmaceutical innovation companies, investment institutions and pharmaceutical press in more than ten cities including Beijing, Shanghai, Guangzhou, Shenzhen, Suzhou, Chengdu also participated in the forum and witnessed the release of the Study on Biomedical Innovation Cities. 

Chairman Chen Deming introduced that the original intention of Study on Biomedical Innovation Cities was to explore and establish a high-quality and complete investment evaluation system in line with the development of China's pharmaceutical innovation cities, and to improve the efficiency of resource allocation. He believed that urban planning, policies, and investment promotion were the key elements to promote the development of the city's innovative biomedical industry.

Chairman Chen Deming Gave a Speech

On behalf of the organizer, Executive President Song Ruilin introduced the current development trend of pharmaceutical industry. He believed that the purpose of Study on Biomedical Innovation Cities was to use international vision and experience to formulate evaluation standards and convey to local governments the key elements that promote the development of city pharmaceutical industry.

Executive President Song Ruilin Gave a Speech

The Forum released the result of Study on Biomedical Innovation Cities, Top 10 China Biomedical Innovation Cities with Most Investment Value and the list of Representative Innovation Cities evaluated by 5 subcategories including biological drugs, medical devices, medical services, medical big data and the biopharmaceutical with the most potentials.

Study Release Conference of “China Biomedical Innovation Cities with Most Investment Value”

Awarding Ceremony of China Biomedical Innovation Cities with Most Investment Value

(Shanghai, Beijing, Guangzhou, Suzhou, Hangzhou, Shenzhen, Nanjing, Chengdu, Wuhan)

Government representatives from Wuhan, Guangzhou and Suzhou introduced their experience of city development.

Li Tao, Deputy Secretary-General of Wuhan Municipal People's Government

He Lulu, Deputy District Mayor of Huangpu District of Guangzhou Development District

Jiang Hua, Deputy Secretary-General of Suzhou Municipal People's Government

Participants agreed that Study on Biomedical Innovation Cities would play a guiding role in the planning and layout of pharmaceutical investors and the government, and jointly promote China’s pharmaceutical innovation and development to the forefront of the world. CBIIC participants witnessed the research results of pharmaceutical innovation cities and felt the leap-forward development of urban pharmaceutical innovation in China.

Plenary Meeting of Biomedical Innovation Cities Development Forum